This study focused on induction therapy and assessed clinical remission at 30 weeks, they add, “but it is also important to determine whether therapeutic drug monitoring might improve durability of treatment effects by maintaining adequate drug levels and preventing ADA formation.”
“Patients with lower drug concentration levels are more likely to develop ADAs. Results might differ in a randomized trial examining the maintenance phase of infliximab treatment rather than induction, especially in less adherent patients who may miss doses, thereby facilitating immunogenicity,” Dr. Curtis and co-authors point out.
The study was funded by grants from the Norwegian Regional Health Authorities and the South-Eastern Norway Regional Health Authorities. The sponsor of the study was Diakonhjemmet Hospital.
References
- Syversen SW, Goll GL, Jørgensen KK, et al. Effect of therapeutic drug monitoring vs. standard therapy during infliximab induction on disease remission in patients with chronic immune-mediated inflammatory diseases: A randomized clinical trial. JAMA. 2021 May 4;325(17):1744–1754.
- Curtis JR, Ogdie A, George MD. Treatment strategies for patients with immune-mediated inflammatory diseases. JAMA. 2021 May 4;325(17):1726–1728.
